Hospital
Mayo Clinic Health System-Southwest Wisconsin Region, INC.
Mayo Clinic Health System-Southwest Wisconsin Region, INC. was paid $13.43M by Medicaid between Jan 2018 and Dec 2024, across 381 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.1% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-SOUTHWEST WISCONSIN REGION, INC.
LA CROSSE, WI 54601
LA CROSSE, WI 54601
33aNPI1801874227assigned 01/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.43M
24GClaims858,987
24DCodes billed381
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#13 of 60
Median peer was paid$2.90M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BORTNEM, MARK controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 117,943 | $1.64M | |
| 2019 | 115,087 | $1.70M | |
| 2020 | 104,298 | $1.80M | |
| 2021 | 144,803 | $2.55M | |
| 2022 | 137,618 | $2.27M | |
| 2023 | 140,983 | $1.97M | |
| 2024incomplete | 98,255 | $1.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 17,353 | 14,997 | $1.09M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.9% | 16,303 | 14,459 | $1.06M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 7.1% | 59,591 | 41,807 | $951K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.5% | 8,134 | 5,367 | $743K |
| 80053 | Comprehensive metabolic panel | 4.5% | 26,621 | 21,813 | $599K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.4% | 12,018 | 10,419 | $595K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 14,448 | 12,160 | $537K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 4,378 | 3,955 | $334K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 19,463 | 15,117 | $290K |
| 87507 | 2.0% | 900 | 831 | $262K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 5,159 | 3,396 | $243K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 3,813 | 3,437 | $211K |
369 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,484 | $208K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 6,205 | $191K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 6,174 | $187K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 3,493 | $182K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 36,297 | $175K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.3% | 5,104 | $171K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 2,657 | $164K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.1% | 13,148 | $151K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 2,786 | $146K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 1,888 | $138K |
| 87631 | <1% | 1,668 | $134K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 8,969 | $132K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,858 | $129K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,051 | $126K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,274 | $118K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 875 | $109K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,182 | $108K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,119 | $105K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,939 | $98K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,463 | $94K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,014 | $93K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,729 | $92K |
| 80061 | Lipid panel | <1% | 8,356 | $79K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,800 | $76K |
| G0127 | Trimming of dystrophic nails, any number | <1% | 2,088 | $75K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 446 | $74K |
| 87480 | <1% | 4,164 | $71K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,183 | $69K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,288 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,017 | $65K |
| 87510 | <1% | 4,167 | $63K | |
| 87660 | <1% | 4,164 | $63K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,992 | $62K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,269 | $62K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,089 | $62K |
| 82948 | <1% | 6,596 | $58K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 904 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,954 | $53K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 769 | $49K |
| 84484 | <1% | 5,627 | $46K | |
| 95886 | <1% | 917 | $44K | |
| 87077 | <1% | 4,251 | $44K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,093 | $43K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 852 | $42K |
| 81025 | <1% | 5,130 | $42K | |
| 87070 | <1% | 2,354 | $41K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 2,567 | $41K |
| 82728 | <1% | 3,927 | $40K | |
| 87653 | <1% | 1,127 | $40K | |
| 81001 | <1% | 11,817 | $39K | |
| 83880 | <1% | 2,860 | $38K | |
| G0378 | Hospital observation service, per hour | <1% | 10,414 | $37K |
| 76830 | Ultrasound, transvaginal | <1% | 1,037 | $36K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 95 | $36K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 447 | $36K |
| 80050 | General health panel | <1% | 1,079 | $36K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,814 | $35K |
| 59025 | Fetal non-stress test | <1% | 620 | $35K |
| 76801 | <1% | 541 | $34K | |
| 80306 | <1% | 2,277 | $33K | |
| 84702 | <1% | 1,882 | $30K | |
| 76642 | <1% | 975 | $29K | |
| 83690 | <1% | 6,091 | $29K | |
| 82947 | <1% | 5,774 | $29K | |
| 85610 | <1% | 11,129 | $28K | |
| 93325 | <1% | 656 | $27K | |
| 86803 | <1% | 2,297 | $27K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,233 | $27K |
| 83605 | <1% | 4,134 | $27K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,252 | $27K |
| 85027 | <1% | 6,382 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,603 | $25K |
| 83735 | <1% | 6,994 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,583 | $24K |
| 82607 | <1% | 2,589 | $24K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 842 | $24K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,099 | $22K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 9,502 | $21K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,768 | $21K |
| 86850 | <1% | 2,904 | $21K | |
| 87186 | <1% | 3,615 | $20K | |
| 93971 | <1% | 817 | $20K | |
| 20610 | <1% | 1,602 | $20K | |
| 72100 | <1% | 1,425 | $20K | |
| 87340 | <1% | 2,307 | $19K | |
| 87103 | <1% | 1,988 | $19K | |
| 86780 | <1% | 2,076 | $19K | |
| 82565 | <1% | 2,583 | $19K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 403 | $18K |
| 85379 | <1% | 2,751 | $18K | |
| 87040 | <1% | 3,788 | $17K | |
| 88142 | <1% | 895 | $17K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 433 | $17K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 312 | $17K |
| 73630 | <1% | 2,042 | $17K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,357 | $17K |
| 73030 | <1% | 1,496 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,080 | $16K |
| 84439 | <1% | 1,946 | $16K | |
| 71250 | <1% | 828 | $15K | |
| 81003 | <1% | 6,212 | $14K | |
| 83550 | <1% | 2,579 | $14K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,223 | $14K |
| 93321 | <1% | 199 | $13K | |
| 82077 | <1% | 1,517 | $13K | |
| 73610 | <1% | 1,467 | $13K | |
| 82570 | <1% | 3,455 | $13K | |
| 86140 | <1% | 4,352 | $13K | |
| 93296 | <1% | 695 | $13K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 33 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 745 | $12K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,424 | $12K |
| 74018 | <1% | 668 | $11K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 119 | $11K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 194 | $11K |
| 83540 | <1% | 2,606 | $11K | |
| 97162 | <1% | 1,878 | $11K | |
| 20611 | <1% | 883 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 131 | $10K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,045 | $10K |
| 83970 | <1% | 430 | $10K | |
| 82043 | <1% | 2,459 | $10K | |
| 82746 | <1% | 1,239 | $10K | |
| 93976 | <1% | 307 | $9K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 217 | $9K |
| 73502 | <1% | 1,139 | $9K | |
| 80143 | <1% | 908 | $9K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $9K |
| 86480 | <1% | 243 | $9K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 356 | $9K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 150 | $9K |
| 80179 | <1% | 847 | $8K | |
| 96367 | <1% | 154 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 275 | $8K |
| 77080 | <1% | 478 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 436 | $8K |
| 84153 | <1% | 630 | $7K | |
| 86769 | <1% | 370 | $7K | |
| 82248 | <1% | 2,834 | $7K | |
| 82805 | <1% | 433 | $7K | |
| 90715 | <1% | 733 | $7K | |
| 82247 | <1% | 423 | $6K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 13 | $6K |
| 80047 | <1% | 146 | $6K | |
| 90686 | <1% | 1,832 | $6K | |
| 73130 | <1% | 635 | $6K | |
| 62323 | <1% | 51 | $5K | |
| 86618 | <1% | 386 | $5K | |
| 73564 | <1% | 969 | $5K | |
| 86900 | <1% | 2,184 | $5K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 293 | $5K |
| 73562 | <1% | 733 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,170 | $5K |
| 73110 | <1% | 486 | $5K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 972 | $5K |
| 76770 | <1% | 156 | $5K | |
| 92567 | <1% | 482 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,914 | $5K |
| 84460 | <1% | 1,282 | $4K | |
| 84450 | <1% | 1,361 | $4K | |
| 92557 | <1% | 586 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,844 | $4K |
| 86901 | <1% | 2,194 | $4K | |
| 96368 | <1% | 55 | $4K | |
| 80076 | <1% | 454 | $4K | |
| 84132 | <1% | 913 | $4K | |
| 91322 | <1% | 583 | $4K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 43 | $3K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 195 | $3K |
| 84156 | <1% | 780 | $3K | |
| 69210 | <1% | 414 | $3K | |
| 82550 | <1% | 638 | $3K | |
| 86706 | <1% | 365 | $3K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 136 | $3K |
| 85018 | <1% | 1,206 | $3K | |
| 97166 | <1% | 352 | $3K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 150 | $3K |
| 80069 | <1% | 242 | $2K | |
| 97161 | <1% | 600 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,769 | $2K |
| 77091 | <1% | 367 | $2K | |
| 86762 | <1% | 193 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 131 | $2K |
| 83516 | <1% | 368 | $2K | |
| 94729 | <1% | 200 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 120 | $2K |
| 93351 | <1% | 27 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 762 | $2K |
| 88342 | <1% | 578 | $2K | |
| 92134 | <1% | 1,940 | $2K | |
| 36591 | <1% | 319 | $2K | |
| 82950 | <1% | 335 | $2K | |
| 93017 | <1% | 42 | $2K | |
| 84165 | <1% | 196 | $2K | |
| 97165 | <1% | 353 | $2K | |
| 99024 | <1% | 865 | $2K | |
| 84100 | <1% | 710 | $2K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 44 | $1K |
| 85652 | <1% | 904 | $1K | |
| 64493 | <1% | 18 | $1K | |
| 86787 | <1% | 218 | $1K | |
| 93225 | <1% | 102 | $1K | |
| 90677 | <1% | 359 | $1K | |
| 64494 | <1% | 23 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 256 | $1K |
| 0753T | <1% | 571 | $1K | |
| 88304 | <1% | 460 | $1K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 221 | $1K |
| 77066 | Tomosynthesis, mammo | <1% | 143 | $1K |
| 97116 | <1% | 595 | $1K | |
| 90480 | <1% | 582 | $1K | |
| 86704 | <1% | 131 | $955.38 | |
| 82784 | <1% | 143 | $935.84 | |
| 77062 | <1% | 58 | $888.14 | |
| 90662 | <1% | 1,422 | $881.06 | |
| 70498 | <1% | 13 | $876.35 | |
| 52000 | <1% | 28 | $875.15 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 296 | $836.51 |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 223 | $828.29 |
| J0178 | Injection, aflibercept, 1 mg | <1% | 75 | $818.59 |
| 36416 | <1% | 2,445 | $817.40 | |
| 90750 | <1% | 248 | $798.11 | |
| 72141 | <1% | 15 | $792.51 | |
| 95800 | <1% | 14 | $786.58 | |
| 86431 | <1% | 173 | $761.77 | |
| 96376 | <1% | 2,892 | $753.66 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 52 | $742.61 |
| G0008 | Administration of influenza virus vaccine | <1% | 1,989 | $724.52 |
| 72040 | <1% | 40 | $663.07 | |
| 84075 | <1% | 112 | $658.00 | |
| 74183 | <1% | 13 | $625.84 | |
| 11721 | <1% | 105 | $601.16 | |
| 11102 | <1% | 14 | $584.63 | |
| 86364 | <1% | 71 | $511.71 | |
| 99205 | Prolong outpt/office vis | <1% | 146 | $492.38 |
| 99496 | <1% | 273 | $463.40 | |
| 94762 | <1% | 82 | $455.44 | |
| J3490 | Unclassified drugs | <1% | 2,598 | $452.37 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 99 | $450.08 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 28 | $442.25 |
| 0097U | <1% | 386 | $421.90 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 38 | $418.32 |
| 11056 | <1% | 37 | $383.65 | |
| 77061 | <1% | 14 | $381.17 | |
| 93226 | <1% | 102 | $328.72 | |
| 84155 | <1% | 169 | $327.82 | |
| 29581 | <1% | 264 | $327.61 | |
| 94060 | <1% | 141 | $295.23 | |
| 76942 | <1% | 265 | $293.63 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 54 | $271.80 |
| 98926 | <1% | 95 | $263.12 | |
| 84550 | <1% | 156 | $256.69 | |
| 76376 | <1% | 563 | $247.63 | |
| 85730 | <1% | 71 | $235.38 | |
| 83615 | <1% | 93 | $227.01 | |
| 83001 | <1% | 13 | $215.88 | |
| J2704 | Injection, propofol, 10 mg | <1% | 20,590 | $166.28 |
| 0004A | <1% | 139 | $156.83 | |
| 0054A | <1% | 323 | $148.74 | |
| 64615 | <1% | 26 | $143.85 | |
| 84146 | <1% | 12 | $137.60 | |
| 51798 | <1% | 272 | $134.51 | |
| 94726 | <1% | 162 | $132.82 | |
| 0124A | <1% | 335 | $132.05 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,227 | $127.96 |
| 80164 | <1% | 12 | $122.20 | |
| 0001A | <1% | 17 | $120.81 | |
| 87075 | <1% | 30 | $119.16 | |
| 85014 | <1% | 90 | $114.40 | |
| 82040 | <1% | 47 | $113.55 | |
| 82310 | <1% | 31 | $111.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,027 | $107.55 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,966 | $105.36 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,821 | $97.47 |
| 73080 | <1% | 28 | $92.44 | |
| 84295 | <1% | 29 | $86.43 | |
| 81015 | <1% | 220 | $84.49 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,764 | $79.11 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 331 | $77.04 |
| 96523 | <1% | 15 | $70.75 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,581 | $69.61 |
| 90656 | <1% | 124 | $69.44 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,859 | $65.60 |
| 82375 | <1% | 15 | $52.20 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,687 | $50.30 |
| 11719 | <1% | 14 | $44.26 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,893 | $43.87 |
| 92133 | <1% | 87 | $42.41 | |
| 84560 | <1% | 19 | $42.14 | |
| 92083 | <1% | 71 | $40.86 | |
| 73590 | <1% | 13 | $40.80 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 518 | $40.60 |
| 87147 | <1% | 12 | $36.35 | |
| 0764T | <1% | 88 | $30.78 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 283 | $23.19 |
| 88141 | <1% | 12 | $23.09 | |
| 83050 | <1% | 14 | $16.90 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,786 | $15.16 |
| 92015 | Determination of refractive state | <1% | 17 | $11.88 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 246 | $10.28 |
| 90739 | <1% | 40 | $8.82 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 832 | $7.92 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 627 | $5.67 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,832 | $5.53 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,372 | $4.93 |
| 90732 | <1% | 98 | $3.68 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 841 | $3.35 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,874 | $3.09 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,195 | $2.93 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 19 | $2.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 349 | $1.42 |
| 82465 | <1% | 31 | $0.18 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 57 | $0.16 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 347 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 65 | $0.00 |
| A9270 | Non-covered item or service | 0% | 8,052 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 643 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 272 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 252 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 2,830 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 815 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 129 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| 99495 | 0% | 132 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 717 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 858 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 91 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 86 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 45 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 59 | $0.00 |
| 17000 | 0% | 24 | $0.00 | |
| 88300 | 0% | 25 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 34 | $0.00 |
| 90632 | 0% | 12 | $0.00 | |
| 0134A | 0% | 16 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| 0064A | 0% | 44 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| 91305 | 0% | 129 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 13 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 17 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 29 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,933 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 207 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 2,413 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 100 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 425 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 135 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 449 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 39 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 71 | $0.00 |
| 91312 | 0% | 70 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 35 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 495 | $0.00 |
| 91300 | 0% | 15 | $0.00 | |
| 97542 | 0% | 13 | $0.00 | |
| 0003A | 0% | 21 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 25 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 72 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 12 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 20 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 30 | $0.00 |
| 83718 | 0% | 16 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 27 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| 0752T | 0% | 15 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBORTNEM, MARK (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.